Q4 2022 Coloplast A/S Earnings Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Coloplast Full Year 2021/2022 Earnings Release Conference Call. (Operator Instructions)
I would now like to turn the conference over to Kristian Villumsen, President and CEO. Please go ahead.
/-&
Thank you very much, operator. Good afternoon and welcome to our full year '21/'22 conference call. I am joined here by our CFO, Anders Lonning-Skovgaard. And our Investor Relations team will start with a short presentation by Anders and myself. And then we'll do what we usually do, open up for questions. Could I ask you all to turn to Slide #3?
We delivered 6% organic growth and a 31% EBIT margin before special items for the financial year. Return on invested capital after tax and before special items was 27%, impacted by the Atos Medical acquisition.
In Q4, we delivered 5% organic growth and a 30% EBIT margin before special items. I'm satisfied with this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |